Introduction/Overview
Natural products, as an important treasure trove for drug discovery, play an irreplaceable role in the history of human disease treatment. Among them, diterpenes have always been a hot topic in medicinal chemistry and pharmacology research due to their structural diversity and significant biological activity. Rhodojaponen II (CAS number: 26116-89-2) is derived from the Rhododendron plant Rhododendron（Rhododendron molle）A diterpenoid compound isolated from the leaves. Although Rhododendron simsii is used in traditional medicine, its toxicity is also well known, and its main toxic components are compounds such as anthocyanins. However, modern pharmacological research has revealed that under specific doses and models, these compounds exhibit potential medicinal value, especially their anti-inflammatory activity has been preliminarily confirmed. What is even more remarkable is that in recent years, research has continuously revealed the multi-target and multi pathway inhibitory activity of anthocyanins II in the field of anti-tumor, transforming it from a traditional toxin to a highly promising anti-tumor lead compound. This article aims to systematically review the chemical properties, plant sources, pharmacological activities, molecular mechanisms of action, pharmacological evaluation, and clinical application prospects of Naoyanghuasu II, in order to provide comprehensive academic references for the in-depth research and development of this compound.
Chemical structure and physicochemical properties
Naoyanghuasu II belongs to the Grayanane type diterpenoid compound, with a molecular formula of C22H34O7 and a molecular weight of 410.5070. The core structure of this compound is a unique five ring system, containing multiple oxygen-containing functional groups such as hydroxyl and epoxy groups, which have a decisive impact on its biological activity and physicochemical properties.
From the analysis of physical and chemical properties, the lipid water partition coefficient (LogP) of Naoyanghuasu II is 1.0056, indicating that it has moderate lipophilicity, which is beneficial for its penetration of cell membranes, but may also affect its distribution in the aqueous phase. Its topological polar surface area (TPSA) is 119.7500 Å ², which is relatively high and mainly attributed to multiple hydroxyl and ether oxygen atoms in the molecule, suggesting the formation of a strong hydrogen bonding network. The predicted value of water solubility is 0.6392 mg/mL, which belongs to the category of slight solubility and is a key factor to consider in the development of actual formulations. In the preliminary drug risk assessment, Naoyanghuasu II showed low blood-brain barrier permeability, which means it may not easily produce central nervous system side effects or be unsuitable for treating brain tumors. In addition, its hERG inhibition risk prediction is negative, indicating a low potential risk of inducing QT interval prolongation in the heart. The Ames test predicted a value of 0.0, indicating that it may not have direct genetic toxicity, but this still needs to be further confirmed through experiments. These physicochemical and preliminary safety parameters together outline the basic profile of Naoyanghuasu II as a lead compound: it has cell permeability, but its water solubility and blood-brain barrier permeability are the shortcomings that need to be optimized in its pharmaceutical process.
Plant sources and extraction methods
Naoyanghuasu II mainly comes from the Ericaceae family's Rhododendron（Rhododendron molle The leaves, flowers, and roots of Blume G. Don. Rhododendron amurense is widely distributed in the Yangtze River Basin and southern regions of China. It is a medicinal plant with a long history but toxicity. Traditionally, it is used topically to treat rheumatism, rheumatism, pain, and stubborn skin ringworm. However, caution should be exercised when taking it orally.
The extraction and separation of kaempferol II from plant materials typically involves the use of organic solvent extraction combined with modern chromatographic techniques. The conventional process is as follows: first, the dried Rhododendron leaves are crushed, and then extracted or refluxed using polar organic solvents such as methanol, ethanol, or acetone. After the crude extract was concentrated under reduced pressure, gradient extraction was carried out using solvents such as petroleum ether, ethyl acetate, and n-butanol in sequence. The main enrichment of kaempferol II was in the ethyl acetate fraction. Further purification depends on column chromatography technology. Silica gel, reverse phase silica gel (such as ODS) or gel (such as Sephadex LH-20) are often used as stationary phases, and chloroform methanol, petroleum ether ethyl acetate and other solvent systems with different proportions are used for gradient elution. High performance liquid chromatography (HPLC), especially preparative HPLC, is the final key step in obtaining high-purity kaempferol II monomer. In recent years, green extraction technologies such as supercritical fluid extraction and ultrasound assisted extraction have also been explored and applied to improve extraction efficiency and reduce solvent consumption. It should be noted that due to the similar structure of diterpenoid components in Rhododendron simsii, the separation and purification process requires precise process control to obtain high-purity anthocyanins II.
Pharmacological activity research
The pharmacological activity research of Naoyanghuasu II initially focused on its neurotoxic and insecticidal activities, but in recent years, the research focus has shifted to its anti-inflammatory and anti-tumor activities.
1. Anti inflammatory activity:
Preliminary research has confirmed that Naoyanghuasu II exhibits inhibitory effects in various acute and chronic inflammation models. For example, in the rat paw swelling model induced by carrageenan and the mouse ear swelling model induced by xylene, kaempferol II can significantly reduce tissue edema and inflammatory cell infiltration. Its anti-inflammatory effect is related to inhibiting the production of pro-inflammatory mediators such as prostaglandin E2 and nitric oxide, as well as downregulating the expression of key pro-inflammatory cytokines such as tumor necrosis factor - α (TNF - α) and interleukin-6 (IL-6).
2. Antitumor activity:
This is currently the most active field of research on sheep flower extract II. A large number of in vitro experiments have shown that rhododendron II has broad-spectrum and significant proliferation inhibition and apoptosis inducing effects on a variety of human tumor cell lines, including but not limited to breast cancer, liver cancer, lung cancer, colon cancer, ovarian cancer and leukemia cells. Its anti-tumor activity is concentration - and time-dependent. In vivo studies have also been validated in mouse transplant tumor models, showing that kaempferol II can effectively inhibit tumor growth and exhibit lower systemic toxicity potential compared to certain chemotherapy drugs. Its anti-tumor effect is not achieved through a single cytotoxicity, but involves multiple aspects such as cell cycle arrest, induction of apoptosis, inhibition of invasion and metastasis, and reversal of multidrug resistance.
Mechanism of action and molecular targets
The anti-tumor mechanism of Naoyanghuasu II is complex, showing the characteristics of multi-target and multi pathway synergistic intervention. Existing research has preliminarily revealed some key molecular targets and signaling pathways of its action:
1. Inducing cell apoptosis and targeting Bcl-2 family proteins:
Inducing tumor cell apoptosis is one of the core mechanisms of action of kaempferol II. Research has shown that it can downregulate the expression of anti apoptotic proteins Bcl-2 and Mcl-1, while possibly upregulating the expression of pro apoptotic proteins such as Bax, leading to a decrease in mitochondrial membrane potential, release of cytochrome C, and activation of the Caspase cascade reaction, ultimately triggering cell apoptosis. Directly targeting MCL1 and BCL2 is an important step in their pro apoptotic effects.
2. Inhibition of cell proliferation and intervention in signaling pathways:
Naoyanghuasu II can inhibit tumor cell growth by interfering with various proliferation and survival signaling pathways.
* STAT3 signaling pathway: STAT3 is an important oncogenic transcription factor. Naoyanghuasu II can inhibit the phosphorylation (activation) of STAT3, block its nuclear translocation, thereby downregulating the expression of downstream target genes (such as Cyclin D1, Survivor, Bcl-2), inhibiting cell proliferation and promoting apoptosis.
* MAPK/ERK pathway: Research has shown that kaempferol II can inhibit the phosphorylation of MAPK1 (i.e. ERK2) and block the activation of the ERK signaling pathway, which is closely related to its induction of cell cycle arrest (often blocking cells in the G2/M phase).
* HIF-1 α pathway: In the hypoxic microenvironment, kaempferol II can inhibit the stability and transcriptional activity of hypoxia inducible factor-1 α (HIF1A), thereby interfering with the reprogramming of glucose metabolism (Warburg effect) and vascular adaptation of tumor cells, and inhibiting tumor progression.
3. Inhibit tumor invasion and metastasis:
Naoyanghuasu II exhibits anti metastatic potential. It can significantly downregulate the expression and activity of matrix metalloproteinase-2 (MMP2) and MMP-9. MMP2 is a key enzyme for degrading extracellular matrix, and inhibition of its activity can effectively reduce the invasion and migration ability of tumor cells.
4. Interference with DNA metabolism and hormone related targets:
* Topoisomerase inhibition: Naoyanghuasu II has been confirmed to be an inhibitor of topoisomerase I (TOP1) and topoisomerase II alpha (TOP2A). It can interfere with DNA replication and transcription processes, leading to DNA damage and triggering cell cycle checkpoint activation and apoptosis.
* Hormone receptor and synthase regulation: The research on breast cancer suggests that rhododendron II may interfere with the growth of estrogen dependent tumor cells by antagonizing estrogen receptor α (ESR1) signal or inhibiting the activity of aromatase (CYP19A1), which provides a theoretical basis for its application in the treatment of hormone receptor positive breast cancer.
In summary, Naoyanghuasu II forms a multidimensional and networked anti-tumor system by simultaneously acting on multiple key targets such as MCL1, BCL2, STAT3, MAPK1, HIF1A, MMP2, TOP1/2A, ESR1, and CYP19A1, which helps to overcome the deficiency of single target drug resistance.
Evaluation of drug properties and pharmacokinetics
Although Naoyanghuasu II has shown good anti-tumor activity in vitro and preliminary in vivo models, its drug development still faces challenges, and systematic pharmacokinetic studies are relatively lacking.
Drug Evaluation:
Based on its physicochemical properties, Naoyanghuasu II belongs to Class II or IV compounds (low solubility) in the Biopharmaceutical Classification System (BCS). Its moderate LogP value is beneficial for cellular uptake, but its lower water solubility and higher TPSA may limit its oral bioavailability. The low permeability of the blood-brain barrier may prevent central neurotoxicity in the treatment of peripheral tumors, but it also rules out its potential for treating brain tumors. Preliminary computer predictions indicate no risk of hERG inhibition and genetic toxicity (Ames negative), which is a positive signal but must be validated through comprehensive preclinical toxicology experiments (including acute toxicity, long-term toxicity, reproductive toxicity, etc.). The toxicity warning of Rhododendron sibiricum itself requires extremely careful evaluation of the therapeutic window (the range between effective dose and toxic dose) of crocetin II.
Pharmacodynamics:
At present, there are few reports on the systematic pharmacokinetic studies of Naoyanghuasu II. Limited animal experimental data suggests that its oral absorption may be poor and widely distributed in the body, but the metabolic and elimination processes are not yet clear. As a diterpenoid compound, it is likely to undergo extensive phase I metabolism (such as hydroxylation and demethylation) and phase II binding reactions (such as glucuronidation) in the liver through cytochrome P450 enzyme systems (such as CYP3A4). The activity and toxicity of its metabolites need to be studied. Developing appropriate drug delivery systems, such as nano formulations (liposomes, polymer micelles), cyclodextrin inclusion complexes, or prodrug strategies, to improve their water solubility, stability, and targeting is a key step in promoting their clinical application.
Clinical application prospects and prospects
As a multi-target anti-tumor natural lead compound, Naoyanghuasu II has broad clinical application prospects, but the road ahead is long and full of challenges.
Prospect:
1. Development of novel multi-target anti-tumor drugs: Its unique multi target mechanism of action provides new candidate molecules for the development of innovative drugs for the treatment of breast cancer, liver cancer, lung cancer and other solid tumors and blood tumors. Especially for patients who develop resistance to existing targeted therapies, multi-target drugs may provide new treatment options.
2. Synergistic agents for combination therapy: The combination of Naoyanghuasu II with existing chemotherapy drugs (such as topoisomerase inhibitors, taxanes) or targeted drugs may produce synergistic effects, reduce their respective dosages, thereby reducing toxic side effects and overcoming or delaying the development of drug resistance.
3. Exploration of the application of anti-inflammatory related diseases: Based on its clear anti-inflammatory activity, it also has potential value in the prevention and treatment of chronic inflammatory diseases (such as rheumatoid arthritis) or inflammation related tumors.
Challenges and Prospects:
1. Accurate definition of treatment window: This is the core challenge of its development. It is necessary to conduct rigorous preclinical studies to clarify the safe and effective dosage range, balance its efficacy with potential toxicity (especially neuromuscular toxicity).
2. Pharmacokinetic optimization: It is urgent to carry out systematic ADME (absorption, distribution, metabolism, excretion) research and use pharmaceutical methods to improve its bioavailability.
3. Deep analysis of the mechanism of action: It is necessary to use chemical biology methods (such as affinity fishing, proteomics) to find its direct target and draw a more accurate molecular action network map.
4. Research on Structure Modification and Structure Activity Relationship: By using it as the parent nucleus for systematic structural modification, it is expected to obtain derivatives or analogues with higher activity, lower toxicity, and better pharmacokinetic properties.
5. Compliant preclinical and clinical studies: Ultimately, it is necessary to complete a full set of preclinical evaluations in accordance with international standards and advance clinical trials to verify their safety and efficacy in humans.
Conclusion
Naoyanghuasu II is a diterpenoid compound with significant research value discovered from the traditional toxic plant Rhododendron simsii. It has successfully achieved a cognitive transformation from a "toxin" to a "potential drug lead". The current research fully confirms its strong potential for multi pathway inhibition in anti-tumor by acting on multiple key targets such as MCL1, STAT3, TOP2A, etc. Although it faces challenges in drug formulation such as water solubility and pharmacokinetics, these challenges are precisely the areas that modern medicinal chemistry and pharmacy can focus on addressing. In the future, through interdisciplinary collaboration and in-depth research on its mechanism of action, structural optimization, formulation innovation, and system toxicology, Naoyanghuasu II is expected to be developed into a new type of anti-tumor drug derived from traditional Chinese medicine that acts on multiple targets, providing a new weapon for the treatment of malignant tumors and a classic example for modern research on natural products.
